Meta Biomed Co., Ltd.
KKRX:0592103,680.00
KRW
-50.00
(-1.34%)
ISIN
KR7059210005
Return %
Stock
S&P 500
1Y
-38.36
14.39
3Y
6.67
81.42
5Y
20.46
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Seok-Song Oh
- Full Time Employees
- 345
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Cheongju-si South Korea
- IPO Date
- Apr 15, 2008
- Website
- meta-biomed.com
- Similar Companies
- Business
- Meta Biomed Co., Ltd. is a South Korea-based medical device manufacturer primarily engaged in the development, production, and global commercialization of specialized dental materials, endodontic equipment, and biodegradable surgical sutures. Founded in 1990 and headquartered in Cheongju-si, Chungcheongbuk-do, South Korea, the company operates through two core business divisions: Dental Materials and Medical Devices. Its dental product portfolio includes endodontic root canal obturation and filling systems; bioceramic root canal sealers marketed under the CeraSeal brand; calcium hydroxide paste formulations including Metapex and Metapaste; resin-based root canal sealers such as ADSEAL; gutta-percha and absorbent paper points; restorative dental materials including Nexcomp and Nexcomp Flow light-cured composite resins; dental etching and bonding agents; and cordless obturation devices and ultrasonic endodontic equipment under the EQ-V series. The company's medical device division specializes in absorbable and non-absorbable surgical sutures manufactured from biomaterials such as polyglycolic acid (PGA), polyglactin 910 (PGLA), polydioxanone (PDO), and poliglecaprone 25 (PGCL); surgical mesh; ophthalmic sutures; and specialized catheter systems including the i-Dolphin epidural catheter. Meta Biomed distributes its products across more than 100 countries worldwide, supported by international subsidiaries including Meta Biomed Inc. in the United States, Meta Biomed Europe GmbH in Germany, and regional operating entities in China and Southeast Asia. In recent operational developments, Meta Biomed has expanded its manufacturing capacity and research and development initiatives focused on next-generation bioceramic dental materials and high-value biodegradable medical polymers. The company has secured enhanced regulatory certifications under the European Union Medical Device Regulation (EU MDR) to accelerate European market penetration, broadened its portfolio of polydioxanone-based aesthetic lifting threads and advanced wound closure solutions, and established expanded distribution alliances across North American and emerging Asian healthcare markets to support sustained export growth.